DelveInsight’s, “Janus Kinase Inhibitor Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Janus Kinase Inhibitor Research. Learn more about our innovative pipeline today! @ Janus Kinase Inhibitor Pipeline Outlook
Key Takeaways from the Janus Kinase Inhibitor Pipeline Report
- In October 2024:- Kartos Therapeutics Inc.- A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib. This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.
- In October 2024:- Pfizer- This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug.
- In October 2024:- Incyte Corporation- A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis. This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
- In October 2024:- Sanofi- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment.
- In October 2024:- Geron Corporation- The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory to Janus Kinase (JAK)-Inhibitor treatment.
- DelveInsight’s Janus Kinase Inhibitor pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Janus Kinase Inhibitor treatment.
- The leading Janus Kinase Inhibitor Companies such as Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis, Biotherapeutics/Reistone Biopharma, and others.
- Promising Janus Kinase Inhibitor Therapies such as Abrocitinib 200 MG Oral Tablet, Ritlecitinib, TL-895, KRT-232, Selinexor 60 mg, Navtemadlin, Ruxolitinib, Imetelstat, and others.
Stay informed about the cutting-edge advancements in Janus Kinase Inhibitor treatments. Download for updates and be a part of the revolution in care @ Janus Kinase Inhibitor Clinical Trials Assessment
Janus Kinase Inhibitor Emerging Drugs Profile
- Povorcitinib: Incyte Corporation
Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor. The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. The drug is also being evaluated in Phase II clinical trials for Prurigo Nodularis, and others. Currently, the drug is in Phase III stage of its development for the treatment of Hidradenitis suppurativa, vitiligo.
- CPL409116: Celon Pharma
CPL 409116 is the first in class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases. CPL’116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint. Currently the drug is in Phase II stage of development for autoimmune indications including in patients with rheumatoid arthritis with coexisting interstitial lung disease.
- ATI-2138: Aclaris Therapeutics
ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor that is being developed as a potential therapeutic option across a variety of T cell-mediated diseases. ITK is a T cell receptor activated kinase involved in driving T cell effector functions while JAK3 is a non-receptor tyrosine kinase responsible for the signal transduction of common gamma receptor cytokines, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. In blocking both T cell receptor function and cytokine signaling, ATI-2138 has potential utility in T cell driven diseases. ATI-2138 is currently in clinical development and its safety and efficacy has not been evaluated by regulatory authorities.
- SDC 1802: Sareum
SDC-1802 is an investigational Sareum’s TYK2/JAK1 preclinical development candidate molecule that demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. Sareum is progressing SDC-1802 through preclinical development and pending satisfactory progress, into human clinical trials. SDC-1802 has the potential to act as a back-up molecule for these autoimmune indications. Currently, the drug is in Preclinical stage of its development for the treatment of cancer.
Learn more about Janus Kinase Inhibitor Drugs opportunities in our groundbreaking Janus Kinase Inhibitor Research and development projects @ Janus Kinase Inhibitor Unmet Needs
Janus Kinase Inhibitor Companies
Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis, Biotherapeutics/Reistone Biopharma, and others.
Janus Kinase (JAK) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Janus Kinase Inhibitor Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Discover the latest advancements in Janus Kinase Inhibitor treatment by visiting our website. Stay informed about how we’re transforming the future of disease @ Janus Kinase Inhibitor Market Drivers and Barriers, and Future Perspectives
Scope of the Janus Kinase Inhibitor Pipeline Report
- Coverage- Global
- Janus Kinase Inhibitor Companies- Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis, Biotherapeutics/Reistone Biopharma, and others.
- Janus Kinase Inhibitor Therapies- Abrocitinib 200 MG Oral Tablet, Ritlecitinib, TL-895, KRT-232, Selinexor 60 mg, Navtemadlin, Ruxolitinib, Imetelstat, and others.
- Janus Kinase Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Janus Kinase Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Janus Kinase Inhibitor Pipeline on our website @ Janus Kinase Inhibitor Emerging Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Janus Kinase (JAK) Inhibitor: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Janus Kinase (JAK) Inhibitor– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Povorcitinib: Incyte Corporation
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- CPL409116: Celon Pharma
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ATI-2138: Aclaris Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- SDC 1802: Sareum
- Drug profiles in the detailed report…..
- Inactive Products
- Janus Kinase (JAK) Inhibitor Key Companies
- Janus Kinase (JAK) Inhibitor Key Products
- Janus Kinase (JAK) Inhibitor- Unmet Needs
- Janus Kinase (JAK) Inhibitor- Market Drivers and Barriers
- Janus Kinase (JAK) Inhibitor- Future Perspectives and Conclusion
- Janus Kinase (JAK) Inhibitor Analyst Views
- Janus Kinase (JAK) Inhibitor Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/